Advertisement
Advertisement
TAK
Takeda Pharmaceutical Company Limited - ADR
16.70
USDSponsored
+0.12
+0.69%
May 20, 14:16 UTC -4
Open
TAK Earnings Reports
Positive Surprise Ratio
TAK beat 28 of 40 last estimates.
70%
Next Report
Date of Next Report
Jul 28, 2026
Estimate for Q1 27 (Revenue/ EPS)
$1.17T
/$60.70
Implied change from Q4 26 (Revenue/ EPS)
+7.12%
/-490.10%
Implied change from Q1 26 (Revenue/ EPS)
+5.94%
/-23.55%
Takeda Pharmaceutical Company Limited - ADR earnings per share and revenue
On May 13, 2026, TAK reported earnings of -15.56 USD per share (EPS) for Q4 26, beating the estimate of -24.25 USD, resulting in a 35.85% surprise. Revenue reached 1.09 trillion, compared to an expected 1.13 trillion, with a -3.31% difference. The market reacted with a +1.34% price change (close before vs. close after earnings).
Looking ahead to Q1 27, 3 analysts forecast an EPS of 60.70 USD, with revenue projected to reach 1.17 trillion USD, implying an decrease of -490.10% EPS, and increase of 7.12% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
Marker Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.44%
PLUS THERAPEUTICS, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.89
Actual
-$1.05
Surprise
-16.98%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Scienture Holdings, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.08
Surprise
+64.35%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
FAQ
What were Takeda Pharmaceutical Company Limited - ADR's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Takeda Pharmaceutical Company Limited - ADR reported EPS of -$15.56, beating estimates by 35.85%, and revenue of $1.09T, -3.31% below expectations.
How did the market react to Takeda Pharmaceutical Company Limited - ADR's Q4 2026 earnings?
The stock price moved up 1.34%, changed from $16.42 before the earnings release to $16.64 the day after.
When is Takeda Pharmaceutical Company Limited - ADR expected to report next?
The next earning report is scheduled for Jul 28, 2026.
What are the forecasts for Takeda Pharmaceutical Company Limited - ADR's next earnings report?
Based on 3
analysts, Takeda Pharmaceutical Company Limited - ADR is expected to report EPS of $60.70 and revenue of $1.17T for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement